leadf
logo-loader
viewAsiamet Resources Ltd
(
AIM:ARSFRA:0FKOTC:KMGLF
)

Asiamet Resources appoints Indonesian local as new CFO

Based in Jakarta, Aurlianus was most recently managing director of coal miner Baramutiara Prima.

Asiamet Resources -
Asiamet has several projects in development in Indonesia

Asiamet Resources Limited (LON:ARS) has appointed Indonesian local Leonard Aurlianus as its Chief Financial Officer.

Based in Jakarta, Aurlianus was most recently managing director of coal miner Baramutiara Prima.

He will join Asiamet on 1 September 2020 with James Deo, the current CFO, to stay on to complete the relocation of the corporate office function from Melbourne to Jakarta and help on developments currently underway.

Tony Manini, executive chairman of Asiamet, said:  “Leonard’s strong accounting and finance background coupled with broader commercial and executive leadership experience provides a solid foundation for us to complete our corporate relocation from Melbourne to Jakarta and to support the growth of the company as we transition from an explorer-developer to a mine operator.

 “Leonard’s experience in leading an Indonesian operating mine and involvement in debt-equity financings for both private and listed companies in Indonesia will prove valuable as we move into the project financing stage"

Quick facts: Asiamet Resources Ltd

Follow
AIM:ARS

Price: 2.55 GBX

Market Cap: £49.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma presents at European Society for Medical Oncology (ESMO) Congress

Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London on the same day as the company present research at the European Society for Medical Oncology (ESMO) Congress. The firm presented the data from the phase I trial of its RXC004 monotherapy study which is their lead drug candidate,...

7 hours, 10 minutes ago

2 min read